MedTrace Logo

AlloSure Lung Assessment and Metagenomics Outcomes Study

NCT05050955 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 550

Last updated 2026-05-26

No results posted yet for this study

Summary

ALAMO is a prospective, multi-center, perspective, registry of patients receiving LungCare™ (AlloSure®-Lung, AlloMap Lung, and HistoMap) for surveillance post-transplant. This study aims to evaluate the diagnostic performance characteristics of AlloSure Lung (dd-cfDNA) to detect a spectrum of rejection (ACR, AMR) and allograft infection (Bacterial, Viral, Fungal, Mycobacterial, Parasitic).

Conditions

  • Lung Transplant Infection
  • Lung Transplant; Complications
  • Lung Transplant Failure and Rejection

Sponsors & Collaborators

  • CareDx

    lead INDUSTRY

Principal Investigators

  • Debbie Levine · Stanford University

  • Ciara Shaver · Vanderbilt University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-29
Primary Completion
2028-12-31
Completion
2028-12-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05050955 on ClinicalTrials.gov